Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Uncomplicated Urinary Tract Infection Treatment Market Snapshot

The global uncomplicated urinary tract infection treatment market garnered a market value of US$ 5.96 Billion in 2022 and is expected to accumulate a market value of US$ 17 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. Growth of the uncomplicated urinary tract infection treatment market can be attributed to high prevalence of UTIs, increasing antibiotic resistance, and the growing awareness of the importance of proper UTI management. The market for uncomplicated urinary tract infection treatment registered a CAGR of 5.7% in the historical period 2018 to 2022

Urinary tract infections are a common medical condition, particularly among women, and are usually caused by bacteria such as Escherichia coli (E. coli). Uncomplicated UTIs can be treated with antibiotics and other medications, such as pain relievers and urinary analgesics, which are designed to alleviate the symptoms of the infection.

The market for uncomplicated UTI treatments includes a range of prescription and over-the-counter medications, as well as natural remedies and alternative therapies. The market is expected to continue to grow in the coming years as new medications and therapies are developed and as the demand for effective and safe UTI treatments increases.

Report Attribute Details
Expected Market Value (2023) US$ 6.55 Billion
Anticipated Forecast Value (2033) US$ 17 Billion
Projected Growth Rate (2023 to 2033) 10% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Uncomplicated Urinary Tract Infection Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for uncomplicated urinary tract infection treatment reflected a value of 5.7% during the historical period, 2018 to 2022.

The market growth was driven by factors such as the high prevalence of UTIs, increasing antibiotic resistance, and the growing awareness of the importance of proper UTI management.

In terms of regional segmentation, North America accounted for the largest share of the Uncomplicated UTI Treatment Market in 2018, followed by Europe and Asia Pacific. The major players in the Uncomplicated UTI Treatment Market included Merck & Co., Inc., Pfizer Inc., Novartis AG, Bayer AG, and GlaxoSmithKline plc, among others. These companies were focused on product development, strategic partnerships, and mergers and acquisitions to expand their market presence and increase their market share.

Overall, the Uncomplicated UTI Treatment Market has been growing steadily over the past few years and is expected to continue to grow in the coming years, driven by factors such as the increasing demand for effective and safe UTI treatments and the development of new therapies and medications.

Thus, the market for uncomplicated urinary tract infection treatment is expected to register a CAGR of 10% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Uncomplicated Urinary Tract Infection Treatment Market?

High prevalence of UTIs along with increasing antibiotic resistance favoring market growth

UTIs are a common medical condition, particularly among women, and the high prevalence of UTIs drives the demand for UTI treatment products and services. Antibiotic resistance is a growing concern worldwide, and it is particularly relevant in the context of UTI treatment. As antibiotic resistance increases, there is a growing need for new and innovative treatments for UTIs.

There is a growing awareness among patients and healthcare professionals about the importance of proper UTI management. This increased awareness drives demand for effective and safe UTI treatments. The development of new technologies for UTI diagnosis, such as rapid diagnostic tests and point-of-care testing, are driving the growth of the UTI treatment market by enabling faster and more accurate diagnosis of UTIs.

As healthcare expenditure continues to rise worldwide, there is a growing demand for UTI treatment products and services, which are essential for the management of UTIs. The aging population is more susceptible to UTIs due to weakened immune systems and other factors, and this demographic trend is expected to drive the growth of the UTI treatment market.

Availability of treatments shaping landscape for uncomplicated urinary tract infection

Uncomplicated urinary tract infections (UTIs) are usually treated with antibiotics to eliminate the bacteria causing the infection. Some of the most commonly prescribed antibiotics for uncomplicated UTIs include:

  • Nitrofurantoin
  • Trimethoprim-sulfamethoxazole
  • Ciprofloxacin
  • Levofloxacin
  • Amoxicillin-clavulanate

Pain relievers and urinary analgesics may also be prescribed to alleviate the symptoms of the infection, such as pain and burning during urination. These include:

  • Phenazopyridine
  • Ibuprofen
  • Acetaminophen
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Uncomplicated Urinary Tract Infection Treatment Market?

Lack of new drug development and limited awareness of UTI management derailing market growth

Antibiotic resistance is a growing concern worldwide, and it is particularly relevant in the context of UTI treatment. As antibiotic resistance increases, it becomes more difficult to effectively treat UTIs, leading to a growing need for new and innovative treatments. There is a lack of new drug development in the UTI treatment market, which can limit the availability of effective treatment options for patients.

Despite growing awareness of the importance of proper UTI management, there are still many patients and healthcare professionals who may not be fully aware of the best practices for UTI prevention and treatment. Some UTI treatment options, particularly alternative and natural remedies, may not be covered by insurance or reimbursed by healthcare providers, making them less accessible to patients.

In some regions, particularly in developing countries, there may be limited access to healthcare facilities and services, making it difficult for patients to receive proper diagnosis and treatment for UTIs.

Region-Wise Insights

High Prevalence of Uncomplicated UTIs Driving Market Growth in North America?

Increasing awareness of UTI management propelling market growth in North America

The North America Uncomplicated Urinary Tract Infection (UTI) Treatment Market is a significant market segment in the global UTI treatment market. North America is expected to dominate the global UTI treatment market due to several factors, including the high prevalence of UTIs, high healthcare expenditure, and increasing awareness of UTI management.

In the United States, UTIs are one of the most common bacterial infections, with an estimated 8.1 Billion cases reported each year. This high prevalence of UTIs drives demand for UTI treatment products and services in the North American market.

The North American UTI treatment market is also characterized by the presence of key market players, such as F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and Pfizer Inc., among others. These companies are involved in the development and commercialization of UTI treatment products, and they are expected to continue to drive growth in the North American UTI treatment market.

Moreover, initiatives and awareness programs undertaken by government organizations and non-governmental organizations in North America are expected to further boost the market growth. These initiatives focus on raising awareness about the importance of proper UTI management and improving access to UTI treatment products and services. Thus, North America is expected to possess 48% market share for uncomplicated UTIs treatment market in 2023.

Growing Geriatric Population Contributing to Uncomplicated UTIs Market Growth in Europe?

Demand for alternative therapies creating lucrative opportunities for uncomplicated UTIs in Europe

The Europe Uncomplicated Urinary Tract Infection (UTI) Treatment Market is another significant market segment in the global UTI treatment market. Europe is expected to be a major contributor to the global UTI treatment market due to several factors, including the high incidence of UTIs, a growing geriatric population, and increasing demand for alternative therapies.

In Europe, UTIs are one of the most common bacterial infections, affecting Billions of people each year. The high incidence of UTIs drives demand for UTI treatment products and services in the European market. The Europe UTI treatment market is also characterized by the presence of key market players, such as Bayer AG, GlaxoSmithKline plc, and Pfizer Inc., among others. These companies are involved in the development and commercialization of UTI treatment products, and they are expected to continue to drive growth in the European UTI treatment market.

Furthermore, the increasing demand for alternative therapies is expected to further boost the market growth in Europe. Patients are increasingly seeking alternative therapies, such as herbal remedies and probiotics, for UTI treatment, which is driving demand for these products in the European market.

Additionally, government initiatives and awareness programs aimed at improving access to UTI treatment products and services are expected to further boost the market growth in Europe. Thus, Europe is expected to hold 40% market share for uncomplicated UTIs treatment market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Easy Accessibility to Medicines Favoring Growth of Retail Pharmacies for Uncomplicated UTIs Treatment?

Demand for over-the-counter medicines bolstering growth of retail pharmacies for uncomplicated UTI treatment

Retail pharmacies can be a good option for obtaining Uncomplicated Urinary Tract Infection (UTI) treatment medications for patients who do not require hospitalization or intensive monitoring. Retail pharmacies are widely available and convenient for patients to access.

Patients can consult with a pharmacist at a retail pharmacy to receive advice and recommendations on UTI treatment options. In addition, retail pharmacies may offer over-the-counter (OTC) UTI treatment options such as cranberry supplements or pain relief medications. Thus, retail pharmacies are expected to possess 47% market share for uncomplicated UTIs market in 2023.

Market Competition

Key players in the uncomplicated urinary tract infection treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck & Co., Inc., Cipla Inc.

  • GlaxoSmithKline (GSK) has developed several antibiotics that are commonly used for the treatment of Uncomplicated Urinary Tract Infections (UTIs). One of their products is Augmentin, which is a combination of amoxicillin and clavulanic acid, used to treat a variety of bacterial infections including UTIs.
  • Iterum Therapeutics’ Sulopenem has demonstrated potent activity against a broad spectrum of gram-negative and gram-positive bacteria, including those that are resistant to other antibiotics commonly used to treat UTIs. In clinical trials, sulopenem has shown efficacy and safety in the treatment of UTIs caused by multi-drug resistant pathogens.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 6.55 Billion
Market Value in 2033 US$ 17 Billion
Growth Rate CAGR of 10% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Class
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • GlaxoSmithKline
  • Iterum Therapeutics
  • Inmunotek
  • Janssen Pharmaceuticals
  • Fimbrion Therapeutics
  • Pfizer
  • Allergan Plc
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Cipla Inc.
Customization Available Upon Request

Key Segments Profiled in the Uncomplicated Urinary Tract Infection Treatment Industry Survey

Drug Class:

  • Gepotidacin
  • Probenecid
  • Sulfonamide
  • Tetracycline
  • Nitrofuran

Distribution Channel:

  • Hospital Pharmacies
  • Gynaecology and Urology Clinics
  • Retail Pharmacies
  • Online Drug Stores

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

How Big is the Uncomplicated Urinary Tract Infection Treatment Market?

The uncomplicated urinary tract infection treatment market valuation is US$ 6.55 billion in 2023.

What are the Projected Dimensions of the Uncomplicated Urinary Tract Infection Treatment Market by 2033?

The market is likely to surge at a 10% CAGR, reaching US$ 17 billion by 2033.

What is Prominently Fueling the Uncomplicated Urinary Tract Infection Treatment Market?

Rising rates of UTI incidence is prominently fueling the adoption of uncomplicated urinary tract infection treatment.

What is the Key Challenge faced by Market Players?

Key challenge faced by market players include increasing antibiotic resistance.

Which Region Exhibits Significant Profitability Potential for Uncomplicated Urinary Tract Infection Treatment?

North America exhibits significant profitability potential for the treatment due to advanced healthcare infrastructure.

Table of Content

1. Executive Summary | Uncomplicated Urinary Tract Infection Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Gepotidacin

        5.3.2. Probenecid

        5.3.3. Sulfonamide

        5.3.4. Tetracycline

        5.3.5. Nitrofuran

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Gynaecology and Urology Clinics

        6.3.3. Retail Pharmacies

        6.3.4. Online Drug Stores

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. The USA

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. GlaxoSmithKline

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Iterum Therapeutics

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Inmunotek

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Janssen Pharmaceuticals

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Fimbrion Therapeutics

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Pfizer

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Allergan Plc

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Bristol-Myers Squibb

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Merck & Co., Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Cipla Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Urinary Tract Infection (UTI) Treatment Market

Published : January 2024

Healthcare

Urinary Bag Market

Published : June 2023

Healthcare

Urinary Collection Device Market

Published : December 2022

Explore Healthcare Insights

View Reports

Uncomplicated Urinary Tract Infection Treatment Market